DFTX Definium Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:38
Aug 19
Aug 19
The author lists speculative biotech catalysts and best ideas by therapeutic area.
The author lists speculative biotech catalysts and best ideas by therapeutic area as research/watchlist content, not explicit current positions or forward calls.
23:36
Aug 19
Aug 19
Top biotech picks across various therapeutic areas
Author lists these biotech names as their best ideas across various therapeutic areas with the sector near all-time highs.
MED
13:09
Aug 17
Aug 17
Author shares a net conviction chart listing multiple biotech tickers without explicit position.
Author shares a net conviction chart listing multiple biotech tickers without explicit position language, so these are indexed as watch rather than directional calls.
LOW
12:53
Aug 17
Aug 17
Reports widest ownership across specialist funds
"Reports widest Q2 2026 ownership across 95 specialist funds based on 13F filings, no directional view."
MED
12:49
Aug 17
Aug 17
Reports most added positions across funds
"Reports most added positions across specialist funds from Q1 to Q2 2026, no directional view."
MED
11:58
Aug 17
Aug 17
Reports widest Q2 ownership among specialist funds
Reports the widest Q2 2026 ownership across 93 specialist funds based on 13F filings.
MED
11:55
Aug 17
Aug 17
Reports most new positions by specialist funds
Reports the most new positions and fresh initiations by specialist funds in Q2 2026.
MED
11:50
Aug 17
Aug 17
Reports most added positions by specialist funds
Reports the most added positions by specialist funds from Q1 to Q2 2026.
MED
11:27
Aug 15
Aug 15
The author is compiling a research thread of user-recommended non-AI tickers.
The author is compiling a research thread of user-recommended non-AI tickers, listing them as a factual watchlist
LOW
13:50
Jul 05
Jul 05
Author highlights DFTX as a named pick that is up ~200%+ YTD and reiterates long-term bullishness on the psychedelics sector.
Author highlights DFTX as a named pick that is up ~200%+ YTD and reiterates long-term bullishness on the psychedelics sector.
Risk: Small-cap biotech volatility; clinical trial outcomes binary; liquidity risk.
12:54
Jun 28
Jun 28
Speaker reacts to parent's DFTX position with surprise and a vague "early" comment.
Speaker reacts to parent's DFTX position with surprise and a vague "early" comment, but does not state their own directional view or catalyst. No actionable thesis.
MED
18:46
Jun 24
Jun 24
The author celebrates a 420% gain since last year's post but provides no forward-looking.
The author celebrates a 420% gain since last year's post but provides no forward-looking direction or current position disclosure, only past performance.
LOW
20:05
Jun 22
Jun 22
Buy MNMD on the catalyst of RFK Jr. as Health Secretary.
Buy MNMD on the catalyst of RFK Jr. as Health Secretary, expecting favorable policy tailwinds for psychedelic treatments.
MED
20:05
Jun 22
Jun 22
Author endorses investing in psychedelic treatments under RFK Jr.'s appointment and highlights.
Author endorses investing in psychedelic treatments under RFK Jr.'s appointment and highlights MNMD's massive gains from phase 3 results, signaling a forward-looking bullish catalyst.
18:17
Jun 22
Jun 22
Reports MNMD's phase 3 results and +50% price surge, no forward-looking directional commitment.
LOW
13:23
Jun 22
Jun 22
DFTX is a psychedelic stock with positive Phase 3 data for LSD-based depression treatment, up 200% YTD, benefiting from regulatory tailwinds from RFK's HHS.
MED
12:13
Jun 22
Jun 22
Premarket movers show hyperscalers declining while chip stocks rise.
Premarket movers show hyperscalers declining while chip stocks rise, with notable gains in Apogee Therapeutics on an AbbVie acquisition and Getty Images soaring on an OpenAI partnership.
21:57
Jun 08
Jun 08
Author endorses psychedelic stocks as a good sector to be long with massive upside potential.
Author endorses psychedelic stocks as a good sector to be long with massive upside potential, but does not state a personal position in the specific tickers.
About DFTX Analyst Coverage
Buzzberg tracks DFTX (Definium Therapeutics, Inc.) across 7 sources. 1 bullish vs 0 bearish calls from 7 analysts. Sentiment: predominantly bullish (6%). 18 total trade ideas tracked. Latest voices: seedy19tron, thebigberbowski, Quoth the Raven.